News archive

Filter by: Reset

December 2014

- 9 December 2014
- KBI Biopharma
Symphogen A/S Licenses the Selexis SUREtechnology Expression Platform and Cell Line

Symphogen has developed unique technologies for the controlled, reproducible production of highly characterized MAb mixtures manufactured in a single batch.

- 20 October 2014
- Crown Bioscience
Crown Bioscience Announces U.S. Expansion With New Translational Oncology Center

NEW SERVICE CENTER WILL ALLOW THE EXPANSION OF NEW IMMUNOTHERAPY EXPERIMENTAL PLATFORMS TO ADVANCE TRANSLATIONAL MEDICAL RESEARCH AND THE TREATMENT OF CANCERS

- 14 August 2014
- Crown Bioscience
Crown Bioscience Announces Inaugural Symposium to Foster Greater Understanding of Predictive Models in Oncology

INDUSTRY LEADERS WILL DISCUSS USE OF PATIENT-DERIVED XENOGRAFT MODELS TO HELP ACCELERATE ONCOLOGY DRUG DISCOVERY

- 24 June 2014
- KBI Biopharma
Cook Pharmica, LLC and Selexis SA Establish Customized Biologic Drug Development and Manufacturing Services Platform

Preliminary Data from the Successful Proof-of-Concept Program Published in the June Issue of BioProcess International

- 15 May 2014
- Crown Bioscience
Crown Bioscience receives $26.55 million in Series D Funding

INVESTMENT TO FUND RAPID EXPANSION IN TRANSLATIONAL PLATFORM TECHNOLOGIES FOR ONCOLOGY AND METABOLIC DISEASES
- 8 May 2014
- Crown Bioscience
Crown Bioscience Announces Research Collaboration with the National Resource Center for Mutant Mice (NRCMM)

NEW COLLABORATION AIMS TO DEVELOP DISEASE-SPECIFIC EXPERIMENTAL MODELS FOR TRANSLATIONAL MEDICAL RESEARCH

- 24 April 2014
- Crown Bioscience
Crown Bioscience Enters Japanese Market via Strategic Partnership with Shin Nippon Biomedical Laboratories

While Crown is the world’s leading supplier of oncology services, with a global footprint spanning three major continents in North America, Europe and Asia Pacific, Japan is seen as a market with ...
- 22 April 2014
- Crown Bioscience
Crown Bioscience Passes 1000 Model Mark in PDX Collection for Oncology Drug Discovery

SIZE OF COLLECTION ALLOWS FOR MORE INFORMED PRECLINICAL DECISION MAKING ON PROSPECTIVE DRUG CANDIDATES

- 20 February 2014
- KBI Biopharma
Selexis Announces Expansion of R&D License Agreement with Amgen

Under the agreement, Amgen will be able to evaluate the SURE CHO-M Cell Line™ in conjunction with the Selexis SUREtech Vectors™ for improved R&D.

- 13 January 2014
- KBI Biopharma
Opthea Signs Cell Line Development Commercial License Agreement with Selexis SA for Wet AMD Product

“The productivity and speed of stable cell line generation with the SUREtechnology Platform™ is playing a key role in quickly progressing our candidate into clinical development,” said Dr. Megan Ba...